98%
921
2 minutes
20
Introduction: Agents used in antitumour therapy have toxic effects on the cardiovascular system of breast cancer (BC) patients, increasing the risk of cardiovascular disease, which has become the most common non-cancer cause of death in BC patients. Exercise can effectively prevent or reduce the occurrence of cardiotoxicity, however, most BC patients have low levels of physical activity. The Health Action Process Approach (HAPA) model has been successfully applied to encourage patients to adhere to physical exercise. This study aims to explore the impact of exercise interventions based on the HAPA model on the monitoring indicators related to cardiotoxicity in BC patients during chemotherapy, aiming to prevent cardiotoxicity in BC patients and improve their physical activity level, exercise self-efficacy, exercise social support and exercise compliance.
Methods And Analysis: In a protocol for a quasi-randomised controlled trial involving a 4-month intervention, 62 patients with BC will be recruited from a tertiary care centre in China. Participants from the first oncology department will be assigned to the HAPA model-based exercise intervention group (n=31), while participants from the second oncology department will be assigned to the control group that will receive standard exercise guidance (n=31). The primary outcome will be the incidence of cardiotoxicity assessed by Electrocardiogram (ECG). The secondary outcomes will include physical activity level, exercise self-efficacy, exercise social support and exercise compliance, which will be evaluated by the short form of the International Physical Activity Questionnaire (IPAQ-SF), Self-Efficacy for Exercise Scale (SEE), Social Support Scale for Exercise (SSSE), and percentage of achieving the recommended total time of exercise per week. The chi-square test or Mann-Whitney U tests will be applied to compare the differences in ECG results and exercise compliance between the two groups. To evaluate the effect of exercise intervention on IPAQ-SF, SSE and SSSE, repeated measures ANOVA will be employed to examine the group-by-time interactions and main effects.
Ethics And Dissemination: This study has been approved by the Ethics Committee of the First Affiliated Hospital of Dalian Medical University (PJ-KS-KY-2024-267(X)). The results of this study will be published via peer-reviewed publications and presentations at conferences.
Trail Registration Number: ChiCTR2400090672.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12352214 | PMC |
http://dx.doi.org/10.1136/bmjopen-2024-095118 | DOI Listing |
Curr Cardiol Rep
September 2025
Division of Cardiology, Health Sciences Building, University of Washington Medical Center, 1959 NE Pacific StreetSuite #A506D Box 356422, Seattle, WA, 98195, USA.
Purpose Of Review: Patients living with cancer are at risk for significant potential cardiovascular complications as a direct result of cancer treatment or due to underlying comorbid cardiovascular disease. This article reviews the methods of risk stratification as well as pharmacologic and nonpharmacologic approaches to cardioprotection in cardio-oncology.
Recent Findings: Several cancer-specific risk stratification tools have incorporated variables such as age, sex, cancer subtype, traditional cardiovascular risk factors and cancer treatment-related parameters to assess cardiovascular specific risk prior to cancer therapy.
Drug Des Devel Ther
September 2025
Department of Cardiology, Qidong People's Hospital/Qidong Liver Cancer Institute/Affiliated Qidong Hospital of Nantong University, Qidong, Jiangsu, 226200, People's Republic of China.
Cancer therapy-induced cardiotoxicity (CTIC) is a serious and increasingly recognized cause of death and disability among cancer survivors. It frequently necessitates the withdrawal or dose reduction of effective anticancer drugs, limiting therapeutic options and affecting patient outcomes. While CTIC poses a major health risk, the precise cellular and molecular mechanisms responsible for this toxicity remain elusive, which complicates the development of preventive and therapeutic strategies.
View Article and Find Full Text PDFBackground: At present, existing risk scores together with traditional biomarkers such as troponin and brain natriuretic peptide (BNP) are still unable to accurately predict cancer therapy-related cardiac dysfunction (CTRCD). MicroRNAs (miRNAs) have emerged as promising biomarkers for improved identification of high-risk patients; however, limited studies have been performed in patients with HER2-positive breast cancer.
Objectives: To investigate the predictive potential of six serum-derived circulating miRNAs for CTRCD occurrence in patients with early-stage HER2-positive breast cancer receiving trastuzumab (TTZ).
Drug Dev Res
September 2025
R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with "epidermal growth factor receptor (EGFR)" mutations playing a pivotal role in tumor progression and carcinogenesis. "Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)," such as Osimertinib, have significantly improved treatment outcomes by overcoming resistance mechanisms like the T790M mutation. However, Osimertinib's clinical application is limited by cardiotoxicity concerns, necessitating safer alternatives.
View Article and Find Full Text PDFFront Oncol
August 2025
Department of Radiation Oncology, Gazi University School of Medicine, Ankara, Türkiye.
Background: Personalized medicine has transformed disease management by focusing on individual characteristics, driven by advancements in genome mapping and biomarker discoveries.
Objectives: This study aims to develop a predictive model for the early detection of treatment-related cardiac side effects in breast cancer patients by integrating clinical data, high-sensitivity Troponin-T (hs-TropT), radiomics, and dosiomics. The ultimate goal is to identify subclinical cardiotoxicity before clinical symptoms manifest, enabling personalized surveillance strategies.